CEL SCI CORP (CVM)

7.05 0.15 (2.19%)

As of 2025-12-02 08:25:08 EST

Cel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.

Traded asNYSE: CVM
ISINUS1508377066
CIK0000725363
LEI549300FIWOFSETIVMI17
EIN840916344
Sector—
IndustryBiological Products, (No Diagnostic Substances)
CEO—
Employees—
Fiscal Year End0930
Address8229 BOONE BLVD ., VIENNA, VA, 22182
Phone7035069460
Websitehttps://cel-sci.com/
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
CVMCEL SCI CORP2025-12-02 08:25:087.050.152.19
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
CVM0000725363CEL SCI CORPUS1508377066549300FIWOFSETIVMI17840916344NYSE2836Biological Products, (No Diagnostic Substances)0930CO8229 BOONE BLVD .VIENNAVA22182UNITED STATESUS70350694608229 BOONE BLVD., VIENNA, VA, 221828229 BOONE BLVD ., VIENNA, VA, 22182——1983——https://cel-sci.com/100,002,1895,321,3416,882,156Cel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.2025-11-27 19:46:17
This is a preview of the latest data. Subscribe to access the full data.
CVM Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
CVM Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2024100,002,1892,362,8942.4274,107,04124,126,23748.271
202397,639,295-65,929,498-40.306949,980,8046,300,94114.4253
2022163,568,793-431,969,114-72.534343,679,863435,3651.0068
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Eyal TalorChief Scientific Officer2024349,61209,600—6,031613,023
John CiprianoSenior Vice President2024249,56200—31249,593
Geert R. KerstenChief Executive And Financial Officer, Treasurer2024644,091020,475—65,6311,070,554
Patricia B. PrichepSecretary, Senior Vice President2024289,194017,160—9,031542,744
Daniel Zimmerman, Ph.D.Senior Vice President202345,54600—53146,077
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
201144
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue———
Cost Of Revenue———
Gross Profit———
Research And Development Expenses18,161,45122,471,49625,355,346
General And Administrative Expenses8,191,0239,004,57810,707,447
Operating Expenses26,352,47431,476,07436,062,793
Operating Income-26,352,474-31,476,074-36,062,793
Net Income-27,579,921-32,194,303-36,700,681
Earnings Per Share Basic—-0.73-0.87
Earnings Per Share Diluted-0.51—-0.87
Weighted Average Shares Outstanding Basic—44,479,86543,148,888
Weighted Average Shares Outstanding Diluted54,044,989—43,148,888
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents4,738,1734,145,73522,672,138
Marketable Securities Current——0
Accounts Receivable——0
Inventories1,019,9082,248,0722,001,715
Non Trade Receivables———
Other Assets Current294,097520,368762,063
Total Assets Current6,055,6786,918,42025,435,916
Marketable Securities Non Current———
Property Plant And Equipment8,129,75310,188,12611,889,029
Other Assets Non Current———
Total Assets Non Current20,936,08823,609,83025,087,790
Total Assets26,991,76630,528,25050,523,706
Accounts Payable1,448,4672,009,7861,618,290
Deferred Revenue———
Short Term Debt———
Other Liabilities Current566,0421,049,581842,492
Total Liabilities Current4,615,7795,585,8464,663,751
Long Term Debt—9,949,000—
Other Liabilities Non Current125,000125,000125,000
Total Liabilities Non Current9,508,90411,727,51413,696,748
Total Liabilities14,124,68317,313,36018,360,499
Common Stock637,870474,223434,484
Retained Earnings-514,011,861-487,091,396-454,897,093
Accumulated Other Comprehensive Income———
Total Shareholders Equity12,867,08313,214,89032,163,207
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization3,969,1833,958,3343,828,917
Share Based Compensation Expense4,270,1806,286,23111,389,932
Other Non Cash Income Expense——0
Change In Accounts Receivable——-54,922
Change In Inventories172,608-156,727159,430
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable-460,576257,845374,890
Change In Other Liabilities-458,489207,089-16,724
Cash From Operating Activities-18,811,206-22,848,561-18,240,951
Purchases Of Marketable Securities———
Sales Of Marketable Securities———
Acquisition Of Property Plant And Equipment94,875361,892637,892
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities-108,086-372,2625,491,367
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock23,575,000——
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities80,620——
Cash From Financing Activities19,511,7304,694,420-638,426
Change In Cash592,438-18,526,403-13,388,010
Cash At End Of Period4,738,1734,145,73522,672,138
Income Taxes Paid———
Interest Paid923,8071,062,5641,157,069
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share—-0.73-0.87
Price To Earnings Ratio—-51.3751-106.5624
Earnings Growth Rate—-16.092-3.3333
Price Earnings To Growth Ratio—3.192631.9687
Book Value Per Share—0.29710.7454
Price To Book Ratio—126.2337124.3751
Ebitda-22,865,065-27,560,553-33,952,798
Enterprise Value—1,673,967,225.987—
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio—0.7529—
Capital Expenditures1,910,8102,257,4312,054,384
Free Cash Flow-20,722,016-25,105,992-20,295,335
Return On Equity-2.1434-2.4362-1.1411
One Year Beta1.5741.08711.5539
Three Year Beta1.41941.02510.7803
Five Year Beta0.88140.93570.9467
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
KERSTEN GEERT RDirector, Chief Executive Officer2025-09-30570A73,405
PRICHEP PATRICIA BChief Financial Officer2025-09-30466A11,213
TALOR EYALChief Scientific Officer2025-09-30260A5,808
KERSTEN GEERT RDirector, Chief Executive Officer2025-07-2825,000A175,157
PRICHEP PATRICIA BChief Financial Officer2025-07-2812,000A75,127
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
JPMORGAN CHASE & CO2025-09-306479.1429
Advisory Services Network, LLC2025-09-308399.2222
NewEdge Advisors, LLC2025-09-30239269.1923
NORTHERN TRUST CORP2025-09-30130,68614,2059.2
MORGAN STANLEY2025-09-304,3524739.2008
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
VANGUARD INDEX FUNDS2025-09-30Institutional Select SharesVSEMX95,308876,833.60.001
VANGUARD INDEX FUNDS2025-09-30Institutional Plus SharesVEMPX95,308876,833.60.001
VANGUARD INDEX FUNDS2025-09-30ETF SharesVXF95,308876,833.60.001
VANGUARD INDEX FUNDS2025-09-30Institutional SharesVIEIX95,308876,833.60.001
VANGUARD INDEX FUNDS2025-09-30Admiral SharesVEXAX95,308876,833.60.001
This is a preview of the latest data. Subscribe to access the full data.